Dashboard
1
Positive results in Mar 26
- OPERATING CASH FLOW(Y) Highest at CNY 5,918.28 MM
- RAW MATERIAL COST(Y) Fallen by -3.48% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 9.49 times
2
With ROE of 15.58%, it has a expensive valuation with a 2.87 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 70,166 Million (Large Cap)
21.00
NA
2.04%
-0.16
15.58%
3.04
Revenue and Profits:
Net Sales:
6,396 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,315 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.32%
0%
-16.32%
6 Months
-20.33%
0%
-20.33%
1 Year
-31.47%
0%
-31.47%
2 Years
-19.16%
0%
-19.16%
3 Years
-53.16%
0%
-53.16%
4 Years
-71.68%
0%
-71.68%
5 Years
-84.28%
0%
-84.28%
Aier Eye Hospital Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.53%
EBIT Growth (5y)
5.02%
EBIT to Interest (avg)
21.44
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.91
Tax Ratio
21.09%
Dividend Payout Ratio
51.49%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
33.13%
ROE (avg)
21.32%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
3.24
EV to EBIT
15.10
EV to EBITDA
11.17
EV to Capital Employed
3.66
EV to Sales
3.12
PEG Ratio
NA
Dividend Yield
0.85%
ROCE (Latest)
24.21%
ROE (Latest)
15.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
6,396.50
6,026.10
6.15%
Operating Profit (PBDIT) excl Other Income
1,643.80
2,039.00
-19.38%
Interest
63.20
69.50
-9.06%
Exceptional Items
-5.00
3.30
-251.52%
Consolidate Net Profit
1,314.70
1,166.50
12.70%
Operating Profit Margin (Excl OI)
257.00%
242.40%
1.46%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 6.15% vs 15.97% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 12.70% vs 19.96% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
22,321.30
20,948.80
6.55%
Operating Profit (PBDIT) excl Other Income
6,907.10
6,403.10
7.87%
Interest
319.50
300.00
6.50%
Exceptional Items
-62.70
146.60
-142.77%
Consolidate Net Profit
3,473.20
3,736.10
-7.04%
Operating Profit Margin (Excl OI)
209.30%
212.70%
-0.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 6.55% vs 3.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -7.04% vs 2.19% in Dec 2024
About Aier Eye Hospital Group Co., Ltd. 
Aier Eye Hospital Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






